Table 2.
Characteristics of included studies
| Study | Year | Country | Race | Study design | BP types | PPI types | Age (yr) | Patient number | |
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| BP | BP+PPI | ||||||||
| Itoh [6] | 2012 | Japan | Asian | Randomized controlled trial | Risedronate | R | > 50 | 86 | 94 |
| Lee [14] | 2013 | Korea | Asian | Case-control study | Unavailable | O, R, L, P, E | ≥ 65 | 13488 | 2774 |
| Roux [15] | 2012 | France | European | Randomized controlled trial | Risedronate | unavailable | Average ≥ 74 | 2489 | 240 |
| Abrahamsen1 [12] | 2011 | Denmark | European | Population-based cohort study | Alendronate | O, R, L, P, E | 70 > age ≥ 35 | 13116 | 4089 |
| Abrahamsen2 [12] | 2011 | Denmark | European | Population-based cohort study | Alendronate | O, R, L, P, E | ≥ 70 | 14795 | 6088 |
R, rabeprazole; O, omeprazole; L, lansoprazole; P, pantoprazole; E, esomeprazole; BP, bisphosphonate; PPI, proton pump inhibitors.